Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
3 Healthcare Stocks Getting Help From the Aging Population
12:25pm, Monday, 06'th Nov 2023
A record number of Americans are now turning 65, Forbes recently reported, amid tens of millions of Baby Boomers. In fact, according to one report, 76.4 million Baby Boomers are living in America curr
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
11:18am, Friday, 03'rd Nov 2023
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK falls victim of ‘hard to please' pharma market
11:02am, Thursday, 02'nd Nov 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mulling reasons for a subsequent drop in its share price
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
10:16am, Thursday, 02'nd Nov 2023
For conservative investors, including those in and nearing retirement, highly reliable dividend stocks with a growth component are an excellent tool. That's because these equities produce regular inco
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
12:47pm, Wednesday, 01'st Nov 2023
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
GSK receives a mixed City reaction despite raised outlook
12:03pm, Wednesday, 01'st Nov 2023
GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financial guidance. Shore Capital Markets praise the “s
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
08:16am, Wednesday, 01'st Nov 2023
GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.09 per share a year ago.
GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch
06:38am, Wednesday, 01'st Nov 2023
High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.
GSK raises outlook amid strong demand for new RSV vaccine
03:31am, Wednesday, 01'st Nov 2023
GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respiratory treatment in the US. The pharmaceuticals co
GSK raises annual forecasts again on strong Arexvy launch
03:05am, Wednesday, 01'st Nov 2023
GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its
GSK Reports Earnings Wednesday. What to Watch.
05:00pm, Tuesday, 31'st Oct 2023
The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.
Pfizer RSV vaccine lags GSK's as head-to-head competition underway
06:35am, Monday, 30'th Oct 2023
Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this s
GSK says endometrial cancer drug meets primary goal in late-stage trial
03:16am, Monday, 30'th Oct 2023
British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.
3 Deeply Undervalued Growth Stocks
12:28pm, Friday, 27'th Oct 2023
One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks
GSK shingles vaccine to underpin third quarter update
07:21am, Friday, 27'th Oct 2023
Strong sales of its shingles vaccine Shingrix has already seen GSK upgrade its forecasts for 2023. The pharmaceutical giant now expects turnover to increase by 8-10%, up from the previous estimate
